Global Fragile X Syndrome Market Research Report 2019-2025

Description

In 2019, the market size of Fragile X Syndrome is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Fragile X Syndrome.

This report studies the global market size of Fragile X Syndrome, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Fragile X Syndrome sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Aelis Farma SAS
Alcobra Ltd
AMO Pharma Limited
Confluence Pharmaceuticals LLC
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Marinus Pharmaceuticals, Inc.
MI.TO. Technology S.r.L.
Neuren Pharmaceuticals Limited
Ovid Therapeutics Inc.
Sage Therapeutics, Inc.
Zynerba Pharmaceuticals, Inc.

Market Segment by Product Type
ACT-01
AMO-01
ANAVEX-273
AUT-00206
Bryostatin-1
Cannabidiol
Others

Market Segment by Application
Clinic
Hopital
Research Center

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Fragile X Syndrome status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Fragile X Syndrome manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Fragile X Syndrome are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

TABLE OF CONTENT

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Fragile X Syndrome Market Size Growth Rate by Type (2019-2025)
1.3.2 ACT-01
1.3.3 AMO-01
1.3.4 ANAVEX-273
1.3.5 AUT-00206
1.3.6 Bryostatin-1
1.3.7 Cannabidiol
1.3.8 Others
1.4 Market Segment by Application
1.4.1 Global Fragile X Syndrome Market Share by Application (2019-2025)
1.4.2 Clinic
1.4.3 Hopital
1.4.4 Research Center
1.5 Study Objectives
1.6 Years Considered

2 Global Growth Trends
2.1 Global Fragile X Syndrome Market Size
2.1.1 Global Fragile X Syndrome Revenue 2014-2025
2.1.2 Global Fragile X Syndrome Sales 2014-2025
2.2 Fragile X Syndrome Growth Rate by Regions
2.2.1 Global Fragile X Syndrome Sales by Regions 2014-2019
2.2.2 Global Fragile X Syndrome Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers

3 Market Share by Manufacturers
3.1 Fragile X Syndrome Sales by Manufacturers
3.1.1 Fragile X Syndrome Sales by Manufacturers 2014-2019
3.1.2 Fragile X Syndrome Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Fragile X Syndrome Revenue by Manufacturers (2014-2019)
3.2.2 Fragile X Syndrome Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Fragile X Syndrome Market Concentration Ratio (CR5 and HHI)
3.3 Fragile X Syndrome Price by Manufacturers
3.4 Key Manufacturers Fragile X Syndrome Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Fragile X Syndrome Market
3.6 Key Manufacturers Fragile X Syndrome Product Offered
3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 ACT-01 Sales and Revenue (2014-2019)
4.1.2 AMO-01 Sales and Revenue (2014-2019)
4.1.3 ANAVEX-273 Sales and Revenue (2014-2019)
4.1.4 AUT-00206 Sales and Revenue (2014-2019)
4.1.5 Bryostatin-1 Sales and Revenue (2014-2019)
4.1.6 Cannabidiol Sales and Revenue (2014-2019)
4.1.7 Others Sales and Revenue (2014-2019)
4.2 Global Fragile X Syndrome Sales Market Share by Type
4.3 Global Fragile X Syndrome Revenue Market Share by Type
4.4 Fragile X Syndrome Price by Type

5 Market Size by Application
5.1 Overview
5.2 Global Fragile X Syndrome Sales by Application

6 United States
6.1 United States Fragile X Syndrome Breakdown Data by Company
6.2 United States Fragile X Syndrome Breakdown Data by Type
6.3 United States Fragile X Syndrome Breakdown Data by Application

7 European Union
7.1 European Union Fragile X Syndrome Breakdown Data by Company
7.2 European Union Fragile X Syndrome Breakdown Data by Type
7.3 European Union Fragile X Syndrome Breakdown Data by Application

8 China
8.1 China Fragile X Syndrome Breakdown Data by Company
8.2 China Fragile X Syndrome Breakdown Data by Type
8.3 China Fragile X Syndrome Breakdown Data by Application

9 Rest of World
9.1 Rest of World Fragile X Syndrome Breakdown Data by Company
9.2 Rest of World Fragile X Syndrome Breakdown Data by Type
9.3 Rest of World Fragile X Syndrome Breakdown Data by Application
9.4 Rest of World Fragile X Syndrome Breakdown Data by Countries
9.4.1 Rest of World Fragile X Syndrome Sales by Countries
9.4.2 Rest of World Fragile X Syndrome Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia

10 Company Profiles
10.1 Aelis Farma SAS
10.1.1 Aelis Farma SAS Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Fragile X Syndrome
10.1.4 Fragile X Syndrome Product Introduction
10.1.5 Aelis Farma SAS Recent Development
10.2 Alcobra Ltd
10.2.1 Alcobra Ltd Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Fragile X Syndrome
10.2.4 Fragile X Syndrome Product Introduction
10.2.5 Alcobra Ltd Recent Development
10.3 AMO Pharma Limited
10.3.1 AMO Pharma Limited Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Fragile X Syndrome
10.3.4 Fragile X Syndrome Product Introduction
10.3.5 AMO Pharma Limited Recent Development
10.4 Confluence Pharmaceuticals LLC
10.4.1 Confluence Pharmaceuticals LLC Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Fragile X Syndrome
10.4.4 Fragile X Syndrome Product Introduction
10.4.5 Confluence Pharmaceuticals LLC Recent Development
10.5 Eli Lilly and Company
10.5.1 Eli Lilly and Company Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Fragile X Syndrome
10.5.4 Fragile X Syndrome Product Introduction
10.5.5 Eli Lilly and Company Recent Development
10.6 F. Hoffmann-La Roche Ltd.
10.6.1 F. Hoffmann-La Roche Ltd. Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Fragile X Syndrome
10.6.4 Fragile X Syndrome Product Introduction
10.6.5 F. Hoffmann-La Roche Ltd. Recent Development
10.7 Marinus Pharmaceuticals, Inc.
10.7.1 Marinus Pharmaceuticals, Inc. Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Fragile X Syndrome
10.7.4 Fragile X Syndrome Product Introduction
10.7.5 Marinus Pharmaceuticals, Inc. Recent Development
10.8 MI.TO. Technology S.r.L.
10.8.1 MI.TO. Technology S.r.L. Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Fragile X Syndrome
10.8.4 Fragile X Syndrome Product Introduction
10.8.5 MI.TO. Technology S.r.L. Recent Development
10.9 Neuren Pharmaceuticals Limited
10.9.1 Neuren Pharmaceuticals Limited Company Details
10.9.2 Company Description and Business Overview
10.9.3 Sales, Revenue and Market Share of Fragile X Syndrome
10.9.4 Fragile X Syndrome Product Introduction
10.9.5 Neuren Pharmaceuticals Limited Recent Development
10.10 Ovid Therapeutics Inc.
10.10.1 Ovid Therapeutics Inc. Company Details
10.10.2 Company Description and Business Overview
10.10.3 Sales, Revenue and Market Share of Fragile X Syndrome
10.10.4 Fragile X Syndrome Product Introduction
10.10.5 Ovid Therapeutics Inc. Recent Development
10.11 Sage Therapeutics, Inc.
10.12 Zynerba Pharmaceuticals, Inc.

11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Fragile X Syndrome Sales Channels
11.2.2 Fragile X Syndrome Distributors
11.3 Fragile X Syndrome Customers

12 Market Forecast
12.1 Global Fragile X Syndrome Sales and Revenue Forecast 2019-2025
12.2 Global Fragile X Syndrome Sales Forecast by Type
12.3 Global Fragile X Syndrome Sales Forecast by Application
12.4 Fragile X Syndrome Forecast by Regions
12.4.1 Global Fragile X Syndrome Sales Forecast by Regions 2019-2025
12.4.2 Global Fragile X Syndrome Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India

13 Research Findings and Conclusion

14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer

Choose License Type

Checkout Inquiry Sample